---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-096946"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:41:10.537078+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Theriva presents preclinical data for VCN-12 oncolytic adenovirus at ESGCT congress

## Summary
- VCN-12, derived from VCN-01, armed with transgenes to improve tumor lysis, stroma degradation, and antitumor immune response.
- Presentation at ESGCT 2025 in Seville, Spain on October 8, 2025, by co-founder Dr. Ramón Alemany.
- Preclinical study published in Human Gene Therapy shows intracranial VCN-01 administration feasible for brain tumor treatment.
- Study concludes findings provide strong rationale for VCN-01 development as therapy for brain tumors.
- No financial guidance or material changes to business operations announced.

## SEC filing metadata
- accession: 0001104659-25-096946
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925096946/0001104659-25-096946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925096946/tm2528055d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-096946
- JSON: https://secwatch.observer/filing/0001104659-25-096946.json
- Plain text: https://secwatch.observer/filing/0001104659-25-096946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.